

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/015206 A2

(51) International Patent Classification⁷: **G01N 33/48**

(21) International Application Number:
PCT/EP2004/008860

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/493,985 8 August 2003 (08.08.2003) US
60/493 599 8 August 2003 (08.08.2003) US
60/493,867 8 August 2003 (08.08.2003) US
60/493,836 8 August 2003 (08.08.2003) US

(71) Applicant (for all designated States except US): **GENOVA LTD.**; Canon's Court, 22 Victoria Street, Hamilton HM 12 (BM).

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Viena (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARGOUD-PUY, Guilaine** [FR/CH]; c/o GeneProt, Inc., 2 Pré de la Fontaine, CH-1217 Meyrin/GE (CH). **BEDERR, Nas-sima** [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin/GE (CH). **BOUGUELERET, Lydie** [FR/CH]; c/o GeneProt, Inc., Case Postale 125, 1217 Meyrin 2/GE (CH). **CUSIN, Isabelle** [FR/CH]; c/o GeneProt, Inc., 2, rue Pre-de-la-Fontaine, CH-1217 Meyrin/GE (CH). **MAHE, Eva** [FR/CH]; C/O GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin/GE (CH). **NIKNEJAD,**

Anne [CH/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin/GE (CH). **REFFAS, Samia** [CH/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin/GE (CH). **ROSE, Keith** [GB/CH]; c/o GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin (CH). **SAUDRAIS, Cédric** [FR/CH]; C/O GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin/GE (CH). **SCHERER, Andreas** [DE/DE]; Kirchstrasse 11, 79618 Rheinfelden-Herten (DE). **PAPOIAN, Ruben** [US/CH]; Güterstrasse 43, CH-4053 Basel (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, 4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS**

(57) Abstract: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.



WO 2005/015206 A2